The incidence of atypical fibroxanthoma and pleomorphic dermal sarcoma in Denmark from 2002 to 2022

Olivia Fruergaard; Mathias Ørholt; Peter Viktor Vester-Glowinski; David Hebbelstrup Jensen

doi:10.1016/j.suronc.2024.102147

The incidence of atypical fibroxanthoma and pleomorphic dermal sarcoma in Denmark from 2002 to 2022

Surg Oncol. 2024 Sep 26:57:102147. doi: 10.1016/j.suronc.2024.102147. Online ahead of print.

Authors

Olivia Fruergaard¹, Mathias Ørholt², Peter Viktor Vester-Glowinski², David Hebbelstrup Jensen³

Affiliations

¹ Department of Plastic Surgery and Burns Treatment, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Electronic address: [email protected].
² Department of Plastic Surgery and Burns Treatment, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
³ Department of Plastic Surgery and Burns Treatment, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Electronic address: [email protected].

PMID: 39388966
DOI: 10.1016/j.suronc.2024.102147

Abstract

Background: The purpose of this study was to assess trends in the incidence rates and overall survival of atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) in the Danish population from 2002 to 2022.

Methods: We included all patients diagnosed with AFX or PDS in the Danish National Pathology Register (DNPR) during the study period. We computed the age-adjusted incidence rate (AAIR) per 100,000 and the average annual percent change (AAPC) and developed an age-period-cohort (APC) model of incidence.

Results: We included a total of 1118 patients, 78.3 % of whom were men. The median age upon diagnosis for AFX and PDS was 77.6 and 78.4 years, respectively. 84.5 % of the 1118 patients received an AFX diagnosis, while 15.5 % received a PDS diagnosis. The AAIR rose from 0.2 per 100,000 individuals in 2002 to 0.5 per 100,000 by 2022, with a peak increase of 0.75 per 100,000 in 2014. The AAPC for both tumors was 5.3 (95 % CI 2.9 %-7.7 %). We found a significant difference in overall survival between AFX and PDS, with PDS having worse overall survival than AFX.

Conclusion: This study, which included the largest non-selected national population to date, found a significant increase in the incidence of AFX and PDS between 2002 and 2015, followed by a decrease.